Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialResearch in context

Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialResearch in context

Summary: Background: MET exon14 skipping mutations (METex14) is an established actionable driver oncogene of non-small-cell lung cancer (NSCLC). While ensartinib is a known second-generation tyrosine kinase inhibitor with primary activity against ALK translocation, it is also classified as a type I...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang Xia, Panwen Tian, Mo Zhou, Jun Zhao, Yang Jin, Zhiyuan Guo, Xiuzhen Li, Weina Lu, Da Miao, Yuefei Lu, Wanting Xu, Yongchang Zhang, Xiuning Le, Wen Li
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:EClinicalMedicine
Subjects:
Ensartinib
NSCLC
MET exon 14 skipping mutation
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537025000318
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items